

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/981,020 10/16/2001		Daniel S. Kohane	0492611-0417 (MIT 8966)	0492611-0417 (MIT 8966) 5504	
24280	7590 06/30/2005		EXAMINER		
CHOATE, HALL & STEWART LLP			FUBARA, BLESSING M		
EXCHANGE	PLACE				
53 STATE STREET			ART UNIT	PAPER NUMBER	
BOSTON, MA 02109			1618		

DATE MAILED: 06/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.	Applicant(s)	
09/981,020	KOHANE ET AL.	
Examiner	Art Unit	
Blessing M. Fubara	1618	

Advisory Action	09/981,020	KOHANE ET AL.				
Before the Filing of an Appeal Brief	Examiner	Art Unit				
	Blessing M. Fubara	1618				
The MAILING DATE of this communication appe	ars on the cover sheet with the d	correspondence add	ress			
THE REPLY FILED 09 June 2005 FAILS TO PLACE THIS APP	PLICATION IN CONDITION FOR A	ALLOWANCE.				
 The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expiresmonths from the mailing date of the final rejection. 						
The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO						
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)).					
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL						
2. The Notice of Appeal was filed on <u>09 June 2005</u> . A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).						
<u>AMENDMENTS</u>						
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below);						
(b) They raise the issue of new matter (see NOTE belo	w);					
(c) ☐ They are not deemed to place the application in being appeal; and/or	tter form for appeal by materially re	educing or simplifying	the issues for			
(d) They present additional claims without canceling a	corresponding number of finally re	jected claims.				
NOTE: There is no reference to any portion of the						
microparticles are not liposome requires further search and consideration. Liposome is mentioned in the instant disclosure in relation to intrathecal injection of liposomes and phospholipids (paragraphs [0139] and [0152]) and that mention does not appear to be related to the instant invention and recitation of liposome may be new matter as it relates to the invention. Liposomes that are lyophilized are solids and in the case when the liposomes are dried, they are not destroyed but can be rehydrated (see Vanlerberghe in US 4,247,411; abstract and column 2 line 3 to column 3 line 22 as a teaching reference). (See 37 CFR 1.116 and 41.33(a)).						
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).						
 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling 						
the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:		vill be entered and an	explanation of			
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected:						
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE						
8. The affidavit or other evidence filed after a final action, because applicant failed to provide a showing of good an and was not earlier presented. See 37 CFR 1.116(e).						
 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 						
	11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:					
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper	No(s)				

13. Other:

U.S. Patent and Trademark Office PTOL-303 (Rev. 4-05)

Advisory Action Before the Filing of an Appeal Brief

Part of Paper No. 20050622

THURMAN IS PAGE
SUPERVISORY PATENT EXAMINER **TECHNOLOGY CENTER 1600**